<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31177739</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-6450</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi</Title><ISOAbbreviation>Zhonghua Liu Xing Bing Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Observation on safety of sequential vaccination schedule of different strain inactivated poliovirus vaccines].</ArticleTitle><Pagination><StartPage>565</StartPage><EndPage>570</EndPage><MedlinePgn>565-570</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0254-6450.2019.05.014</ELocationID><Abstract><AbstractText><b>Objective:</b> To evaluate the safety of population based sequential vaccination schedule of inactivated poliovirus vaccines prepared with different strains. <b>Methods:</b> This randomized, parallel-group controlled trial was conducted from March, 2017 to May, 2018, in Shanghai. Adverse reaction data of Sabin strain inactivated polio vaccine (sIPV), wild strains inactivated polio vaccines (wIPV) and bivalent types &#x2160; and &#x2162; oral poliomyelitis vaccine (bOPV) were systematically collected through active observation in 1 917 infants in Shanghai after the vaccination at 2, 3, 4 months old. The eligible infants aged 2 months were divided into 4 groups: &#x2460;sIPV+sIPV+bOPV group; &#x2461;sIPV+wIPV+bOPV group; &#x2462;wIPV+sIPV+bOPV group; &#x2463;wIPV+wIPV+bOPV group. <b>Results:</b> The incidence of adverse reaction 30 days later after 3 basic dose vaccinations was 16.79% (946/5 633). No serious adverse reaction was reported. Local and systemic reactions were mainly mild. Common local reactions were pain, erythema, cutaneous nodule, <i>etc</i>.; and common systemic reactions were abnormal crying, drowsiness, diarrhea and appetite lost, <i>etc</i>.. The incidence of local reactions 30 days later after 3 basic dose vaccinations was 1.65% (93/5 633), and the incidence rates of grade 1-3 reactions were1.26% (71/5 633), 0.21% (12/5 633) and 0.20% (11/5 633) respectively. The incidence rate of systemic reactions 30 days later after 3 basic vaccinations was 15.14% (853/5 633), and the incidence rates of grade 1-3 reactions were 11.33% (638/5 633), 3.18% (179/5 633) and 0.64% (36/5 633) respectively. There were no significant differences in the rate of grade 3 reaction among different groups (<i>&#x3c7;</i>(2)=4.17, <i>P</i>=0.24). <b>Conclusions:</b> No severe adverse reactions related to sequential vaccination of different strain inactivated polio vaccines were observed, most of reactions were mild and all of them were cured. It is safe to use sIPV and wIPV simultaneously or alternately for childhood sequential vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>X D</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>L L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>J Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>J N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Biological Product, Chaoyang District Center for Disease Control and Prevention, Beijing 100021, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>15GWZK0101, GWIV-1</GrantID><Agency>The Fourth Round of the Three-Year Public Health Action Plan of Shanghai</Agency><Country/></Grant><Grant><GrantID>Q2017A3124</GrantID><Agency>Chinese Preventive Medicine Association Vaccine and Immunization Talent Lifting Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Liu Xing Bing Xue Za Zhi</MedlineTA><NlmUniqueID>8208604</NlmUniqueID><ISSNLinking>0254-6450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x8bc4;&#x4ef7;&#x4f7f;&#x7528;&#x4e0d;&#x540c;&#x6bd2;&#x682a;&#x810a;&#x9ad3;&#x7070;&#x8d28;&#x708e;&#x706d;&#x6d3b;&#x75ab;&#x82d7;&#xff08;IPV&#xff09;&#x5f00;&#x5c55;&#x5e8f;&#x8d2f;&#x514d;&#x75ab;&#x7a0b;&#x5e8f;&#x5728;&#x5927;&#x89c4;&#x6a21;&#x4eba;&#x7fa4;&#x4e2d;&#x4f7f;&#x7528;&#x7684;&#x5b89;&#x5168;&#x6027;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x4e8e;2017&#x5e74;3&#x6708;&#x81f3;2018&#x5e74;5&#x6708;&#xff0c;&#x91c7;&#x7528;&#x968f;&#x673a;&#x3001;&#x5e73;&#x884c;&#x5bf9;&#x7167;&#x8bbe;&#x8ba1;&#xff0c;&#x4ee5;Sabin&#x682a;&#x810a;&#x9ad3;&#x7070;&#x8d28;&#x708e;&#x706d;&#x6d3b;&#x75ab;&#x82d7;&#xff08;sIPV&#xff09;&#x3001;&#x91ce;&#x6bd2;&#x682a;&#x810a;&#x9ad3;&#x7070;&#x8d28;&#x708e;&#x706d;&#x6d3b;&#x75ab;&#x82d7;&#xff08;wIPV&#xff09;&#x548c;&#x2160;+&#x2162;&#x578b;&#x810a;&#x9ad3;&#x7070;&#x8d28;&#x708e;&#x51cf;&#x6bd2;&#x6d3b;&#x75ab;&#x82d7;&#xff08;bOPV&#xff09;&#x4f5c;&#x4e3a;&#x7814;&#x7a76;&#x75ab;&#x82d7;&#xff0c;&#x5728;&#x4e0a;&#x6d77;&#x5e02;&#x9009;&#x62e9;1 917&#x4f8b;2&#x6708;&#x9f84;&#x5a74;&#x513f;&#x4e3a;&#x7814;&#x7a76;&#x5bf9;&#x8c61;&#xff0c;&#x5206;&#x4e3a;4&#x7ec4;&#xff1a;&#x2460;sIPV+sIPV+bOPV&#xff1b;&#x2461;sIPV+wIPV+bOPV&#xff1b;&#x2462;wIPV+sIPV+bOPV&#xff1b;&#x2463;wIPV+wIPV+bOPV&#xff0c;&#x91c7;&#x7528;&#x4e3b;&#x52a8;&#x89c2;&#x5bdf;&#x7684;&#x65b9;&#x6cd5;&#x89c2;&#x5bdf;&#x5176;&#x5728;2&#x3001;3&#x3001;4&#x6708;&#x9f84;&#x63a5;&#x79cd;&#x540e;&#x7684;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> 4&#x7ec4;&#x5b8c;&#x6210;3&#x5242;&#x57fa;&#x7840;&#x514d;&#x75ab;&#x63a5;&#x79cd;&#x540e;&#x603b;&#x7684;&#x4e0d;&#x826f;&#x4e8b;&#x4ef6;&#x53d1;&#x751f;&#x7387;&#x4e3a;16.79%&#xff08;946/5 633&#xff09;&#xff0c;&#x5404;&#x7ec4;&#x5747;&#x672a;&#x62a5;&#x544a;&#x4e25;&#x91cd;&#x4e0d;&#x826f;&#x4e8b;&#x4ef6;&#xff0c;&#x5168;&#x8eab;&#x548c;&#x5c40;&#x90e8;&#x53cd;&#x5e94;&#x5747;&#x4ee5;&#x8f7b;&#x5ea6;&#x53cd;&#x5e94;&#x4e3a;&#x4e3b;&#x3002;&#x5e38;&#x89c1;&#x5c40;&#x90e8;&#x53cd;&#x5e94;&#x4e3a;&#x6ce8;&#x5c04;&#x90e8;&#x4f4d;&#x75bc;&#x75db;&#x3001;&#x7ea2;&#x548c;&#x786c;&#x7ed3;&#x7b49;&#xff1b;&#x5168;&#x8eab;&#x53cd;&#x5e94;&#x4e3a;&#x5f02;&#x5e38;&#x54ed;&#x95f9;&#x3001;&#x55dc;&#x7761;&#x3001;&#x8179;&#x6cfb;&#x548c;&#x98df;&#x6b32;&#x4e0b;&#x964d;&#x7b49;&#x3002;&#x63a5;&#x79cd;&#x540e;30 d&#x5185;&#xff0c;&#x5c40;&#x90e8;&#x53cd;&#x5e94;&#x7387;&#x4e3a;1.65%&#xff08;93/5 633&#xff09;&#xff0c;&#x5176;&#x4e2d;&#x8f7b;&#x5ea6;&#x3001;&#x4e2d;&#x5ea6;&#x548c;&#x91cd;&#x5ea6;&#x53cd;&#x5e94;&#x7387;&#x5206;&#x522b;&#x4e3a;1.26% &#xff08;71/5 633&#xff09;&#x3001;0.21%&#xff08;12/5 633&#xff09;&#x548c;0.20%&#xff08;11/5 633&#xff09;&#xff1b;&#x5168;&#x8eab;&#x53cd;&#x5e94;&#x7387;&#x4e3a;15.14%&#xff08;853/5 633&#xff09;&#xff0c;&#x5176;&#x4e2d;&#x8f7b;&#x5ea6;&#x3001;&#x4e2d;&#x5ea6;&#x548c;&#x91cd;&#x5ea6;&#x53cd;&#x5e94;&#x7387;&#x5206;&#x522b;&#x4e3a;11.33%&#xff08;638/5 633&#xff09;&#x3001;3.18%&#xff08;179/5 633&#xff09;&#x548c;0.64%&#xff08;36/5 633&#xff09;&#x3002;&#x5404;&#x7ec4;&#x95f4;&#x91cd;&#x5ea6;&#x53cd;&#x5e94;&#x7387;&#x5dee;&#x5f02;&#x65e0;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;&#xff08;<i>&#x3c7;</i>(2)=4.17&#xff0c;<i>P</i>=0.24&#xff09;&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> &#x672c;&#x7814;&#x7a76;&#x4e2d;&#x672a;&#x89c2;&#x5bdf;&#x5230;&#x4f7f;&#x7528;&#x4e0d;&#x540c;&#x6bd2;&#x682a;&#x810a;&#x9ad3;&#x7070;&#x8d28;&#x708e;&#x706d;&#x6d3b;&#x75ab;&#x82d7;&#x5f00;&#x5c55;&#x5e8f;&#x8d2f;&#x514d;&#x75ab;&#x7a0b;&#x5e8f;&#x63a5;&#x79cd;&#x76f8;&#x5173;&#x7684;&#x4e25;&#x91cd;&#x4e0d;&#x826f;&#x4e8b;&#x4ef6;&#xff0c;&#x591a;&#x6570;&#x4e3a;&#x8f7b;&#x5ea6;&#x7684;&#x4e0d;&#x826f;&#x53cd;&#x5e94;&#xff0c;&#x6240;&#x6709;&#x53cd;&#x5e94;&#x5747;&#x75ca;&#x6108;&#x3002;&#x540c;&#x65f6;&#x6216;&#x4ea4;&#x66ff;&#x4f7f;&#x7528;sIPV&#x548c;wIPV&#x5f00;&#x5c55;&#x5e8f;&#x8d2f;&#x514d;&#x75ab;&#x7a0b;&#x5e8f;&#x5bf9;&#x4e8e;&#x9002;&#x9f84;&#x513f;&#x7ae5;&#x5747;&#x5177;&#x6709;&#x826f;&#x597d;&#x7684;&#x9884;&#x9632;&#x63a5;&#x79cd;&#x5b89;&#x5168;&#x6027;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inactivated poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Sequential schedule</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31177739</ArticleId><ArticleId IdType="doi">10.3760/cma.j.issn.0254-6450.2019.05.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>